Phase 1b, open-label, multi-center, dose-esalation study of the safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, which consists of a variant of interleukin-2 (IL-2v) that targets carcinoembryonic antigen (CEA), and MPDL32

Cancer type: Solide tumores

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, IL2, PD-L1

Status: Inclusion completed

Link to